Pfizer To Charge $39 Per Coronavirus Vaccine Course To All Developed Countries For Similar Volume Commitments As US

Pfizer Inc. PFE wouldn't give a discount to any developed country for its novel coronavirus (COVID-19) vaccine — over the price it's charging the United States under a contract signed last week — CEO Albert Bourla said at a conference call Tuesday.

What Happened: "All the countries that are developed right now will not receive a lower price for the same volume commitment than the U.S.," Bourla said, as earlier reported by Reuters.

The pharmaceutical company's pre-order deal with the U.S. government prices a single dose of the potential vaccine at $19.5, with the total course of two doses costing $39.

Pfizer could change the prices once the coronavirus outbreak's official status as a pandemic is over, Reuters noted.

The New York-based company began the late-stage clinical trials for its vaccine, co-developed with Germany's BioNTech SE BNTX, on Monday.

Why It Matters: Rival Moderna Inc. MRNA is looking to price its similar vaccine candidate in the range of $50 to $60, according to a report from the Financial Times the same day.

Another vaccine candidate from AstraZeneca plc's AZN appears to be priced around $3 to $4 per dose, under its agreements with the governments of the Netherlands, Germany, France, and Italy, according to an analyst note from SVB Leerink's Geoffrey Porges.

Price Action: Pfizer shares closed about 4% higher at $39.02 on Tuesday, and were unchanged in the after-hours session.

Posted In: BiotechNewsHealth CareGlobalMediaGeneralAlbert BourlaCoronavirusCovid-19PandemicReutersThe Financial Timesvaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...